Access our most up to date scientific developments and breakthroughs by downloading our scientific posters.
From validation of innovative capabilities, to the development of novel technologies and state-of-the-art chemistry, our scientists are proud to share some of their latest achievements.
27th November 2023
Anti-GBM serum induces early onset of autoimmune response and fibrosis in kidney of male Sprague Dawley rats.
FIND OUT MORE7th November 2023
Psilocybin: the relationship between head twitch response, locomotor activity, 5-HT2A ex vivo receptor occupancy and plasma and brain levels of psilocin
FIND OUT MORE2nd November 2023
Preventative effects of dexamethasone in lipopolysaccharide-induced neuroinflammation
FIND OUT MORE27th October 2023
In Vitro Microglia Models as a Screening Platform to Support Neuroinflammation Drug Discovery Programs
FIND OUT MORE25th October 2023
The implantation site impacts the tumour growth kinetics and tumour immune infiltrate in EO771 and 4T1 syngeneic breast cancer models
FIND OUT MORE25th October 2023
Combinations of immune checkpoint inhibitors with fractionated radiotherapy or DNA damage response agents leads to improved anti-tumour responses and modulates the tumour immune microenvironment.
FIND OUT MORE18th October 2023
Dexamethasone and Enalaprilat but not SB525334 exhibit anti-inflammatory properties in precision-cut kidney slices (PCKS) obtained from mice with Adriamycin-induced nephropathy
FIND OUT MORE13th October 2023
Development and Validation of [3H]Cimbi-36 Binding in Mouse Frontal Cortex Including Affinity Constant Determination for Classical Psychedelics: Comparison to [3H]MDL100,907 Binding
FIND OUT MORE9th October 2023
Evaluation of protein biomarkers in brain homogenate and plasma from different animal models of Alzheimer’s Disease: P301S and APP/PSEN1
FIND OUT MORE3rd October 2023
What is Happening in High Throughput Screening at Sygnature Discovery?
FIND OUT MORE3rd October 2023
Establishing assays to investigate combinations of fractioned radiotherapy with DNA damage response agents in vitro and in vivo to enable investigation of radiosensitisation and improved anti-tumour responses.
FIND OUT MORE3rd October 2023
Chemogenomic screening of the NLRP1 pathway
FIND OUT MORE27th September 2023
Assessing the effects of four clinically used analgesics in two mechanistic stimuli-evoked acute pain models in mice demonstrates good predictive nature of the phase 2 of formalin pain model.
FIND OUT MORE27th September 2023
Building a Neuroscience Drug Discovery Platform
FIND OUT MORE27th September 2023
Mitochondrial dysfunction, an in vitro model of neurodegenerative disorders: a focus on multiple endpoints, humanisation, and drug discovery platforms to enable new therapeutic discov
FIND OUT MORE22nd September 2023
ASMS Deployment to Broaden High Throughput Hit Finding Capabilities at Sygnature Discovery
FIND OUT MORE19th September 2023
Characterising the response of tumours to fractioned radiotherapy and immune checkpoint inhibitors
FIND OUT MORE3rd August 2023
Characterising the Irreversible: Using Biophysics to Enable Covalent Drug Discovery
FIND OUT MORE3rd August 2023
Total and Phospho-Tau Levels in an Animal Model of Alzheimer’s Disease: A Cross-Platform Comparison of Biomarker Measurements
FIND OUT MORE5th July 2023
Discovery of Opelconazole (PC945): A Novel Antifungal Agent for inhaled Administration
FIND OUT MORE5th July 2023
Building Diverse Hit-Finding Collections Through Novel Chemistries
FIND OUT MORE27th June 2023
Do current therapies target kidney inflammation?
FIND OUT MORE22nd June 2023
Generation and validation of human monocyte-derived microglia (MDMi); a Sygnature Discovery screening platform for identifying novel anti-neuroinflammatory drugs
FIND OUT MORE25th June 2020
Comparing HTS with the Novel Immuno-Oncology Target HPK1: Unveiling Diverse Chemical Starting Points for Potent Inhibitor Development
FIND OUT MORE25th June 2020
Developing sensitive arrays to facilitate hit identification of RNA modifying enzymes
FIND OUT MORE29th January 2020
HTS for HPK1 Inhibitors: New Automation Platform & Sygnature LeadFinder Library
FIND OUT MORE30th October 2019
Evolution of Compound Library – Screening at Sygnature Discovery
FIND OUT MORE30th October 2019
Optimising Kidney Fibrosis Spheroid Model using Design of Experiment (DoE)
FIND OUT MORE30th October 2019
Development of In Vitro Models of Organ Fibrosis
FIND OUT MORE30th October 2019
Microscale Thermophoresis (MST) as a novel, alternative biophysical method for fragment screening and hit profiling
FIND OUT MORE9th October 2019
Comparing RNAi and CRISPR/Cas9 for Modulating Drug Targets: A Case Study on IKKβ in NFκB Signalling Pathway
FIND OUT MORE9th October 2019
Is Ticlopidine a Suitable Control Compound for Assessing PPB?
FIND OUT MORE27th September 2019
Kinetics of neurite growth dynamics using live cell imaging in different neuronal cell models
FIND OUT MORE26th September 2019
Identification of a Novel Small Molecule Inhibitor of the RNA Demethylase FTO using MST
FIND OUT MORE1st September 2019
Enabling Success in Lead Identification – Development of a HTS Library at Sygnature Discovery
FIND OUT MORE8th April 2019
Glutathione Trapping: Investigating Methods of Detection of Glutathione Adducts
FIND OUT MORE3rd April 2019
Development of a screening assay platform to identify inhibitors of neutrophil NETosis
FIND OUT MORE21st March 2019
Glutathione Trapping: Investigating the Effects of pH and Glutathione Concentration
FIND OUT MORE21st March 2019
Advancing Novel Fragment Hits for Epigenetic Target BRD3: A Structural Approach
FIND OUT MORE20th March 2019
CT7001, a Novel Orally Bio-Available CDK7 Inhibitor, Is Highly Active in in-Vitro and in-Vivo Models of AML
FIND OUT MORE12th October 2018
Optimisation of a high throughput in vitro assay to determine the extent of brain tissue binding and the fraction unbound of potential CNS drugs
FIND OUT MORE24th September 2018
An Efficient, Multifaceted Approach to Indoleamine 2, 3-Dioxygenase (IDO1) Hit Profiling
FIND OUT MORE9th July 2018
Application of Different Neuronal Models to Investigate Glutamate-induced Excitotoxicity in Drug Discovery
FIND OUT MORE1st June 2018
Development of an in vitro Immuno-Oncology platform to aid the Development of Next Generation Cancer Therapeutics
FIND OUT MORE22nd May 2018
Lipophilicity Measurement – Prediction and Impact
FIND OUT MORE21st May 2018
Validation of Non-CYP Mediated Stability Assays
FIND OUT MORE14th April 2018
Characterisation of in vitro Models of Microglia Function to Support Neuroinflammation Drug Discovery
FIND OUT MORE28th January 2018
Synthesis of Substituted Tetrahydrofurans
FIND OUT MORE16th January 2018
Compound Profile of 61 Libraries Delivered to ELF
FIND OUT MORE27th October 2017
A Phenotypic Screen to Identify Novel Neuroprotective Agents
FIND OUT MORE6th October 2017
Assessment of the In Vivo Disposition of Cinchophen in Rat and potential mechanisms of drug-induced liver injury
FIND OUT MORE18th September 2017
Live cell and high content imaging approaches identify apoptosis inducers in cell models of triple negative breast cancer
FIND OUT MORE15th September 2017
A Valuable Tool for Drug Discovery: 3D Cell Assays
FIND OUT MORE12th September 2017
The Analysis and Stabilisation of Tetrahydrobiopterin and Dihydrobiopterin
FIND OUT MORE25th June 2017
Discovery of PC945, a novel antifungal agent for inhaled administration
FIND OUT MORE30th May 2017
Analysis of the First 40 Libraries Delivered to ELF
FIND OUT MORE20th May 2017
Complementary Biophysical Approaches to Assess Fragment Binding
FIND OUT MORE4th February 2017
Adoption of High Content Imaging Capabilities in Support of Integrated Drug Discovery Programmes
FIND OUT MORE18th November 2016
Fragment-based Hit Identification for the Epigenetic Target BRD3
FIND OUT MORE25th October 2016
The use of in vitro ADME techniques in understanding fasiglifam-induced liver injury
FIND OUT MORE25th October 2016
Drug Discovery Approaches for Epigenetic Targets
FIND OUT MORE9th September 2016
Optimisation of a Series of Potent and Selective GR Antagonists
FIND OUT MORE7th June 2016
An Integrated Panel of Assays for the Prediction of Drug-Induced Liver Injury
FIND OUT MORE7th June 2016
Fragment-based Lead Discovery to Identify Novel Bromodomain-Containing Protein 3 Binders
FIND OUT MORE7th June 2016
New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma
FIND OUT MORE7th June 2016
Poster: Epigenetic Target BRD3 – Fragment-based Hit Discovery
FIND OUT MORE28th September 2015
Cyclic Ketones as Building Blocks for Diverse Library Scaffolds
FIND OUT MORE28th September 2015
Azomethine ylide cycloadditions
FIND OUT MORE7th September 2015
PAINS Handout ELRIG Sept 2015 Notes
FIND OUT MORE5th September 2015
Dealing with PAINs in a drug discovery CRO
FIND OUT MORE8th August 2015
Heterogeneous Catalysis: A KeyTool in the Synthesis of sp3-Rich Library Scaffolds
FIND OUT MORE23rd April 2015
FTSA and SPR for identifying small molecule ligands and PAINs
FIND OUT MORE20th April 2015
From Idea to Library: The Process to Deliver 40,000 Unique Lead-like Compounds
FIND OUT MORE24th February 2015
Fragment Library Design and Screening 3
FIND OUT MORE28th July 2014
A Safer Route to Organic Azides Using Segmented Flow
FIND OUT MORE| Cookie | Duration | Description |
|---|---|---|
| __hssrc | session | This cookie is set by Hubspot whenever it changes the session cookie. The __hssrc cookie set to 1 indicates that the user has restarted the browser, and if the cookie does not exist, it is assumed to be a new session. |
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
| Cookie | Duration | Description |
|---|---|---|
| __cf_bm | 30 minutes | This cookie, set by Cloudflare, is used to support Cloudflare Bot Management. |
| __hssc | 30 minutes | HubSpot sets this cookie to keep track of sessions and to determine if HubSpot should increment the session number and timestamps in the __hstc cookie. |
| bcookie | 2 years | LinkedIn sets this cookie from LinkedIn share buttons and ad tags to recognize browser ID. |
| lang | session | This cookie is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website. |
| lidc | 1 day | LinkedIn sets the lidc cookie to facilitate data center selection. |
| pll_language | 1 year | The pll _language cookie is used by Polylang to remember the language selected by the user when returning to the website, and also to get the language information when not available in another way. |
| Cookie | Duration | Description |
|---|---|---|
| _uetsid | 1 day | This cookies are used to collect analytical information about how visitors use the website. This information is used to compile report and improve site. |
| _uetvid | 1 year 24 days | Used by Bing to store and track visits across websites. |
| Cookie | Duration | Description |
|---|---|---|
| __hstc | 1 year 24 days | This is the main cookie set by Hubspot, for tracking visitors. It contains the domain, initial timestamp (first visit), last timestamp (last visit), current timestamp (this visit), and session number (increments for each subsequent session). |
| _ga | 2 years | The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors. |
| _gat_gtag_UA_68772340_1 | 1 minute | This cookie is set by Google and is used to distinguish users. |
| _gcl_au | 3 months | Provided by Google Tag Manager to experiment advertisement efficiency of websites using their services. |
| _gid | 1 day | Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously. |
| _hjAbsoluteSessionInProgress | 30 minutes | Used to detect the first pageview session of a user. 30 minutes duration, extended on user activity. Boolean true/false data type. |
| _hjFirstSeen | 30 minutes | This is set by Hotjar to identify a new user’s first session. It stores a true/false value, indicating whether this was the first time Hotjar saw this user. It is used by Recording filters to identify new user sessions. |
| _hjid | 1 year | This is a Hotjar cookie that is set when the customer first lands on a page using the Hotjar script. |
| _hjIncludedInPageviewSample | 2 minutes | Set to determine if a user is included in the data sampling defined by your site's pageview limit. 2 minutes duration, extended every 30 seconds. Boolean true/false data type. |
| _hjIncludedInSessionSample | 2 minutes | Set to determine if a user is included in the data sampling defined by your site's daily session limit. 2 minutes duration, extended every 30 seconds. Boolean true/false data type. |
| _hjTLDTest | session | We try to store the _hjTLDTest cookie for different URL substring alternatives until it fails. Enables us to try to determine the most generic cookie path to use, instead of page hostname. It means that cookies can be shared across subdomains (where applicable). After this check, the cookie is removed. Session duration. Boolean true/false data type. |
| CONSENT | 16 years 3 months 15 days 12 hours 7 minutes | These cookies are set via embedded youtube-videos. They register anonymous statistical data on for example how many times the video is displayed and what settings are used for playback.No sensitive data is collected unless you log in to your google account, in that case your choices are linked with your account, for example if you click “like” on a video. |
| hubspotutk | 1 year 24 days | This cookie is used by HubSpot to keep track of the visitors to the website. This cookie is passed to Hubspot on form submission and used when deduplicating contacts. |
| vuid | 2 years | Vimeo installs this cookie to collect tracking information by setting a unique ID to embed videos to the website. |
| Cookie | Duration | Description |
|---|---|---|
| bscookie | 2 years | This cookie is a browser ID cookie set by Linked share Buttons and ad tags. |
| IDE | 1 year 24 days | Google DoubleClick IDE cookies are used to store information about how the user uses the website to present them with relevant ads and according to the user profile. |
| MUID | 1 year 24 days | Bing sets this cookie to recognize unique web browsers visiting Microsoft sites. This cookie is used for advertising, site analytics, and other operations. |
| test_cookie | 15 minutes | The test_cookie is set by doubleclick.net and is used to determine if the user's browser supports cookies. |
| VISITOR_INFO1_LIVE | 5 months 27 days | A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface. |
| YSC | session | YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages. |
| yt-remote-connected-devices | never | YouTube sets this cookie to store the video preferences of the user using embedded YouTube video. |
| yt-remote-device-id | never | YouTube sets this cookie to store the video preferences of the user using embedded YouTube video. |
| yt.innertube::nextId | never | These cookies are set via embedded youtube-videos. |
| yt.innertube::requests | never | These cookies are set via embedded youtube-videos. |
| Cookie | Duration | Description |
|---|---|---|
| AnalyticsSyncHistory | 1 month | Used by LinkedIn to store and track visits across websites. |
| cookietest | session | This cookie checks if the user has cookies enabled on their browser. |
| li_gc | 2 years | Used by LinkedIn to store cookie consent preferences. |
| UserMatchHistory | 1 month | Linkedin - Used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences. |